#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14348	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2318	753.7	0	.	n	.	0	A69G	SNP	69	69	A	445	445	G	894	G,A,T,C	648,237,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14348	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2318	753.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1826	1826	T	945	T,C,G,A	938,2,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14348	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2318	753.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1560	1560	C	943	C	943	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14348	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2318	753.7	0	HET	.	.	.	T454TG	.	454	454	T	830	830	T	905	TG,T	656,226	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25170	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4121	762.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1935	1935	A	1002	A,G	1001,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25170	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4121	762.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2569	2569	C	908	C,A,G	905,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25170	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4121	762.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2643	2643	A	897	A	895	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25170	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4121	762.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3195	3195	C	886	C,G	885,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2102	folP	852	852	99.88	folP.l6.c4.ctg.1	2011	130.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1009	1011	AAA	220;219;218	A;A;A	220;219;218	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2102	folP	852	852	99.88	folP.l6.c4.ctg.1	2011	130.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1240	1242	AGC	193;195;196	A,G;G;C	192,1;195;196	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3800	161.8	1	SNP	p	S91F	0	.	.	271	273	TCC	844	846	TCC	184;186;188	T;C;C	184;186;188	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3800	161.8	1	SNP	p	D95N	0	.	.	283	285	GAC	856	858	GAC	191;188;188	G,T,A;A;C	189,1,1;188;188	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3800	161.8	1	SNP	p	D95G	0	.	.	283	285	GAC	856	858	GAC	191;188;188	G,T,A;A;C	189,1,1;188;188	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1956	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1735	140.6	1	SNP	p	G45D	0	.	.	133	135	GGC	722	724	GGC	227;230;232	G;G;C	227;230;232	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1122	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1515	92.5	0	.	n	.	0	A197.	DEL	197	197	A	804	804	A	236	A	236	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4972	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3570	174.0	1	SNP	p	D86N	0	.	.	256	258	GAC	934	936	GAC	243;243;241	G;A;C	243;243;241	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4972	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3570	174.0	1	SNP	p	S87R	0	.	.	259	261	AGT	937	939	AGT	238;238;240	A,C;G,T;T,G	237,1;236,1;238,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4972	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3570	174.0	1	SNP	p	S87W	0	.	.	259	261	AGT	937	939	AGT	238;238;240	A,C;G,T;T,G	237,1;236,1;238,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4972	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3570	174.0	1	SNP	p	S87I	0	.	.	259	261	AGT	937	939	AGT	238;238;240	A,C;G,T;T,G	237,1;236,1;238,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4972	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3570	174.0	1	SNP	p	S88P	0	.	.	262	264	TCC	940	942	TCC	242;243;241	T;C,G;C,T	241;241,1;239,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4246	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3125	169.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1797	1799	GGC	256;254;254	G;G;C	256;254;254	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1422	1424	GCA	225;224;223	G;C,A;A	225;223,1;223	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1425	1427	ATC	223;227;226	A;T;C,A	223;227;225,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1437	1439	GTG	231;234;233	G;T,A;G	231;233,1;233	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1437	1439	GTG	231;234;233	G;T,A;G	231;233,1;233	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1941	1943	ACC	216;218;219	A;C;C	216;218;219	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1995	1997	GCG	217;213;213	G;C;G	217;213;213	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1995	1997	GCG	217;213;213	G;C;G	217;213;213	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2118	2120	GGC	241;241;240	G,C;G;C	240,1;241;240	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2127	2129	GGC	243;244;246	G,A;G;C	241,1;243;246	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4060	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2753	183.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2145	2147	CTG	240;244;244	C;T;G	240;244;244	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5650	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3562	198.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1881	1883	CCG	213;215;213	C,G;C;G	212,1;215;213	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2388	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2395	124.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	860	860	C	190	C,G	189,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	320	porB1a	984	100	95.0	porB1a.l15.c30.ctg.1	182	54.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	62;59;58	A;C;G	62;59;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	320	porB1a	984	100	95.0	porB1a.l15.c30.ctg.1	182	54.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	24;22;18	C;A;A	24;22;18	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	554	556	GAA	265;266;265	G;A;A	265;266;265	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	842	844	GAT	260;261;259	G,A;A;T	259,1;261;259	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	965	967	TCA	290;289;289	T;C;A	290;289;289	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1094	1096	GTC	280;281;279	G,A;T;C,G	279,1;281;278,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1106	1108	TCT	275;274;271	T;C,T;T	275;273,1;271	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1424	1426	GCA	262;263;265	G;C,A;A	262;262,1;265	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	1	SNP	p	G120K	1	.	.	358	360	AAG	800	802	AAG	243;246;247	A;A;G,T	243;246;246,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	1	SNP	p	A121D	1	.	.	361	363	GAC	803	805	GAC	248;251;252	G;A;C	248;251;252	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3172	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1848	212.3	1	SNP	p	D121N	0	.	.	361	363	GAC	803	805	GAC	248;251;252	G;A;C	248;251;252	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10626	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5522	240.3	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2370	2372	AAT	303;305;306	A;A;T,C	303;305;305,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1458	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1540	118.3	1	SNP	p	V57M	1	.	.	169	171	ATG	834	836	ATG	252;252;252	A;T;G	252;252;252	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
